Systolic blood pressure responses to enalapril maleate (MK 421, a new angiotensin converting enzyme inhibitor (CEI) and hydrochlorothiazide (HTZ) were studied in conscious Dahl salt-sensitive (DS) and salt-resistant (DR) rats maintained on a high salt (8.0% NaCl) and a normal salt (0.4% NaCl) diet. The DS rats were severely hypertensive after 3 weeks on the high salt diet whereas the systolic blood pressure (SBP) of the DR rats were normotensive. Oral treatment with enalapril (15-100 mg.kg-1.day-1) and HTZ (60-400 mg.kg-1.day-1) caused a significant reduction of SBP in the DS rats with the high salt diet (P < 0.001); however, this was not observed until after 4 weeks of treatment when the dosage was 30 and 150 mg/kg-1.day-1, respectively. Furthermore, enalapril therapy alone significantly reduced the SBP of all groups of rats regardless of diet or Dahl strain (P < 0.001), but this was not observed until the end of the 7th week of therapy in DR rats on 8.0% NaCl and at the end of the 3rd week of therapy for DR and DS rats on 0.4% NaCl. These results suggest that enalapril may lower SBP by mechanisms other than those related to an action as a CEI.
ASJC Scopus subject areas
- Physiology (medical)